Meeting
2012 ASCO Annual Meeting
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).
Authors
Caicun Zhou
Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
Caicun Zhou , Yi Long Wu , Xiaoqing Liu , Changli Wang , Gongyan Chen , Ji Feng Feng , Shucai Zhang , Jie Wang , Songwen Zhou , Shengxiang Ren , Shun Lu , Li Zhang , Cheng-ping Hu , Yi Luo , Lei Chen , Ming Ye , Jianan Huang , Xiuyi Zhi , Yiping Zhang , Qingyu Xiu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00874419
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7520)
DOI
10.1200/jco.2012.30.15_suppl.7520
Abstract #
7520
Poster Bd #
10
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).
First Author: C. Zhou
Poster
2011 ASCO Annual Meeting
Final overall survival results of NEJ002, a phase 3 trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
First Author: A. Inoue
Poster
2014 ASCO Annual Meeting
Phase II study of biomarker guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on EGFR-mutation status.
First Author: Wenzhao Zhong
